AST2818 mesylate (Synonyms: AST2818) |
| Katalog-Nr.GC33096 |
Alflutinib (Furmonertinib) Mesylat ist ein potenter EGFR-Inhibitor. Alflutinib (Furmonertinib)-Mesylat hemmt aktive EGFR-Mutationen sowie die T790M-erworbene resistente Mutation. Alflutinib (Furmonertinib)-Mesylat hat das Potenzial fÜr die Erforschung von Krebserkrankungen, insbesondere nicht-kleinzelligem Lungenkrebs (NSCLC).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2130958-55-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AST2818 mesylate is an EGFR inhibitor.
AST2818 mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation[1].
[1]. Y.Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial. J Thorac Oncol. 2017 Nov, 12(11): S2138.
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *